Clinical trials: Myocardial Revascularization
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Acute Myocardial Infarction
PROTECT : Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s)
To determine whether the application of ventricular pacing can protect the human heart from damage resulting from a myocardial infarction
- Trial name
- NCT00409604
- Testing
- Temporary RV VVI pacing
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Guidant Corporation
Coronary Artery Disease
Resolute Integrity US Extended Length Sub-Study(RI US XL)
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel…
- Trial name
- RI-US XL (NCT01913600)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medtronic Vascular
Congestive Heart Failure
Extracorporeal Shockwave Myocardial Revascularization (ESMR) Therapy For The Treatment of Chronic Heart Failure
Evaluation of non-invasive treatment modality, using low-intensity extracorporeal shockwaves for treatment of subjects diagnosed with Congestive Heart Failure, with ischemic etiology.
- Trial name
- NCT01251185
- Testing
- Cardiospec
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Medispec
Coronary Artery Disease
Vascular Evaluation for Revascularization: Defining the Indications for Coronary Therapy: A Pilot Study
The present prospective, multicenter study will therefore be performed with the primary objective of establishing the correlation between fractional flow reserve (FFR) and intravascular ultrasound with virtual histology…
- Trial name
- VERDICT (NCT01158053)
- Testing
- FFR and VH-IVUS, IVUS and FFR
- Volunteers
- 291 people
- Sponsor
- Volcano Corporation
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Coronary Artery Disease
The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization
The study will be a prospective, pragmatic, randomized clinical trial of the comparative effectiveness of diagnostic evaluation strategies for stable CAD, to be performed in outpatient settings, including primary care and…
- Trial name
- PRECISE (NCT03702244)
- Testing
- cCTA with selective FFRct
- Where
- United States
- Volunteers
- 2,103 people
- Sponsor
- HeartFlow, Inc.
Cardiovascular Disease
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for…
- Trial name
- NCT07136012
- Testing
- Olpasiran
- Where
- 252 sites in United States, Australia and 1 more
- Volunteers
- 11,000 people
- Sponsor
- Amgen
Ischemia, Cardiac Death
A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions
E.V.O.L.U.T.I.O.N.: A Randomized Study to Evaluate Safety and Efficacy of the Excel Sirolimus Eluting Stent with a Biodegradable Polymer Versus Sirolimus Eluting Stent with a Non-Biodegradable Polymer in the Treatment of Patients…
- Conditions
- Ischemia, Cardiac Death, Myocardial Infarction
- Trial name
- EVOLUTION (NCT00825773)
- Testing
- Percutaneous Transluminal Coronary Angioplasty
- Where
- China
- Volunteers
- 1,944 people
- Sponsor
- JW Medical Systems Ltd
Class IV Angina
CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study
The purpose of this study it to collect real world 30-day and 1-year follow-up data for patients undergoing TMR with the CardioGenesis Holmium:YAG Laser System either as a sole therapy procedure or in conjunction with coronary…
- Trial name
- NCT02694861
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- CryoLife, Inc.
Stable Angina
Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality…
- Trial name
- AGENT-4 (NCT00185263)
- Volunteers
- 116 people
- Sponsor
- Cardium Therapeutics
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Coronary Stenosis
Study Comparing the MiStent SES Versus the XIENCE EES Stent
The primary objective of this study is to compare the performance of MISTENT to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- DESSOLVE III (NCT02385279)
- Testing
- MiStent, XIENCE EES
- Where
- 20 sites in France, Germany and 2 more
- Volunteers
- 1,398 people
- Sponsor
- ECRI bv
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences
Angina Pectoris
A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
The multi-centric, open label, single arm and self controlled study is planned to assess the efficacy of orally administered Sigmart in subjects with recurrent angina after coronary revascularization.
- Trial name
- SIGMART (NCT01185015)
- Testing
- Sigmart (nicorandil)
- Sponsor
- Merck KGaA, Darmstadt, Germany
Coronary Artery Disease
Prospective multicEntric NonranDomized Registry
The purpose of this study is to evaluate the safety and efficacy of the eucaLimus Sirolimus Eluting stent system in patients with de novo coronary lesions.
- Trial name
- ExPEND (NCT02496169)
- Testing
- eucaLimus
- Volunteers
- 400 people
- Sponsor
- Eucatech AG
Angina Pectoris
Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine
This study used a multicenter, prospective cohort study. According to whether they received TCM treatment and the degree of exposure to TCM, the cohorts were divided into strong TCM exposure group, TCM exposure group, weak TCM…
- Trial name
- NCT05482009
- Testing
- Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
The BIOFLOW-VIII registry is a post-market clinical evaluation of the Orsiro Mission stent in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-VIII (NCT04555174)
- Testing
- Orsiro Mission DES
- Where
- 41 sites in France
- Volunteers
- 872 people
- Sponsor
- Biotronik AG
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl